Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Celgene to apply machine learning to market access

Signs agreement for rights to GNS Healthcare's simulation platform

Digital pharma Celgene GNS HealthcareCelgene is set to apply machine learning to market access, commercialisation and drug discovery through a partnership with GNS Healthcare.

GNS applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual patients.

The service and license arrangement with Celgene covers its REFS (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform.

The deal, which involves Celgene's second equity investment in the firm, will also see several GNS causal modeling experts brought in-house at the biopharma company's sites to operate the platform.

Iya Khalil, chief commercial officer and co-founder of GNS, said: “Companies that embrace data-driven frameworks and culture such as Celgene are gaining a competitive advantage to rapidly generate insights that are simply not possible with any other analytics methodology.”

In addition to Celgene, GNS has previously worked with the likes of J&J, Novartis, Covance and the US National Institutes of Health.

5th January 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics